These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38044353)

  • 1. Structure-based identification of novel inhibitors targeting the enoyl-ACP reductase enzyme of Acinetobacter baumannii.
    Khan S; Madhi SA; Olwagen C
    Sci Rep; 2023 Dec; 13(1):21331. PubMed ID: 38044353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
    Kwon J; Mistry T; Ren J; Johnson ME; Mehboob S
    Bioorg Med Chem; 2018 Jan; 26(1):65-76. PubMed ID: 29162308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of promising molecules against MurD ligase from Acinetobacter baumannii: insights from comparative protein modelling, virtual screening, molecular dynamics simulations and MM/PBSA analysis.
    Jha RK; Khan RJ; Amera GM; Singh E; Pathak A; Jain M; Muthukumaran J; Singh AK
    J Mol Model; 2020 Oct; 26(11):304. PubMed ID: 33068184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ternary complex formation of AFN-1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies.
    Rao NK; Nataraj V; Ravi M; Panchariya L; Palai K; Talapati SR; Lakshminarasimhan A; Ramachandra M; Antony T
    Chem Biol Drug Des; 2020 Aug; 96(2):704-713. PubMed ID: 32227402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel compounds against Acinetobacter baumannii 3-oxoacyl-[acyl-carrier-protein] synthase I (FabB) via comprehensive structure-based computational approaches.
    Albayrak E; Koçer S; Mutlu O
    J Mol Graph Model; 2023 Nov; 124():108565. PubMed ID: 37454410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative subtractive proteomics based ranking for antibiotic targets against the dirtiest superbug: Acinetobacter baumannii.
    Ahmad S; Raza S; Uddin R; Azam SS
    J Mol Graph Model; 2018 Jun; 82():74-92. PubMed ID: 29705560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moleculer dynamics simulaiton revealed reciever domain of
    Ahmad S; Shaker B; Ahmad F; Raza S; Azam SS
    J Biomol Struct Dyn; 2019 Jul; 37(11):2897-2912. PubMed ID: 30043709
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of inhibitor binding hotspots in Acinetobacter baumannii β-ketoacyl acyl carrier protein synthase III using molecular dynamics simulation.
    Ha Y; Jang M; Lee S; Lee JY; Lee WC; Bae S; Kang J; Han M; Kim Y
    J Mol Graph Model; 2020 Nov; 100():107669. PubMed ID: 32659632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of putative non-host essential genes and novel drug targets against Acinetobacter baumannii by in silico comparative genome analysis.
    Uddin R; Masood F; Azam SS; Wadood A
    Microb Pathog; 2019 Mar; 128():28-35. PubMed ID: 30550846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens.
    Parker EN; Drown BS; Geddes EJ; Lee HY; Ismail N; Lau GW; Hergenrother PJ
    Nat Microbiol; 2020 Jan; 5(1):67-75. PubMed ID: 31740764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A computational perspective towards the identification of promising lead molecules against 6-hydroxy-methyl dihydropterin pyrophosphokinase (HPPK) from
    Bhati SK; Jain M; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2024 Sep; 42(14):7432-7441. PubMed ID: 37490027
    [No Abstract]   [Full Text] [Related]  

  • 12. C6 Hydroxymethyl-Substituted Carbapenem MA-1-206 Inhibits the Major
    Stewart NK; Toth M; Alqurafi MA; Chai W; Nguyen TQ; Quan P; Lee M; Buynak JD; Smith CA; Vakulenko SB
    mBio; 2022 Jun; 13(3):e0036722. PubMed ID: 35420470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unveiling MurE ligase potential inhibitors for treating multi-drug resistant
    Altharawi A; Alqahatani SM; Alanazi MM; Tahir Ul Qamar M
    J Biomol Struct Dyn; 2024 Mar; 42(5):2358-2368. PubMed ID: 37099644
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Khan S; Madhi SA; Olwagen C
    J Biomol Struct Dyn; 2024; 42(3):1506-1517. PubMed ID: 37105229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of druggable targets for Acinetobacter baumannii via subtractive genomics and plausible inhibitors for MurA and MurB.
    Kaur N; Khokhar M; Jain V; Bharatam PV; Sandhir R; Tewari R
    Appl Biochem Biotechnol; 2013 Sep; 171(2):417-36. PubMed ID: 23846799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of potential lead molecules against prioritised targets of multi-drug-resistant-Acinetobacter baumannii - insights from molecular docking, molecular dynamic simulations and in vitro assays.
    Skariyachan S; Manjunath M; Bachappanavar N
    J Biomol Struct Dyn; 2019 Mar; 37(5):1146-1169. PubMed ID: 29529934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into Acinetobacter baumannii fatty acid synthesis 3-oxoacyl-ACP reductases.
    Cross EM; Adams FG; Waters JK; Aragão D; Eijkelkamp BA; Forwood JK
    Sci Rep; 2021 Mar; 11(1):7050. PubMed ID: 33782435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combating tigecycline resistant Acinetobacter baumannii: A leap forward towards multi-epitope based vaccine discovery.
    Ahmad S; Ranaghan KE; Azam SS
    Eur J Pharm Sci; 2019 Apr; 132():1-17. PubMed ID: 30797936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of
    Mahfuz AMUB; Stambuk Opazo F; Aguilar LF; Iqbal MN
    J Biomol Struct Dyn; 2022 Jun; 40(9):4021-4037. PubMed ID: 33251968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a novel and potent class of FabI-directed antibacterial agents.
    Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.